ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CLPT / earnings
MOBI (50) EMBC (68) OFIX (42) SI (44) ⌘ Pro Terminal →

ClearPoint Neuro Inc. (CLPT) Next Earnings Date & Expected ±11.2% Move

$10.67 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.65

ClearPoint Neuro Inc. (CLPT) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $342.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLPT compare to MOBI and EMBC in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLPT?
▼

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.65 (-0.22%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (5)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
$21 Bull$9 Base$7 Bear
📬 FREE CLPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLPT)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY CLPT SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (32% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$9.81-3.7% Next Q
Q2 (-2Q)
16
Grade E$9.45+2.5% Next Q
Q3 (-1Q)
18
Grade E$9.69+10.1% Next Q
Current
19
Grade E$10.67-12% Hist 90D α
Trajectory: E (15) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLPT currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.32) and Max Pain ($11.20) forces dealer call-delta covering toward $20.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±11.2% Swing Band

±$1.20 Expected Swing
$9.47 (-11.2%)Spot $10.67$11.87 (+11.2%)
MODEL EARNINGS SETUP GAUGE

CLPT Quantitative Pre-Earnings Setup: 19/100

Trailing EPS: $4.25 • YoY Revenue Growth: 17.8%

Model Bullish Setup (19/100)Model Risk Weight (81/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$37.0M-$25.5M-$24.4M61.4%
FY 20242024-12-31$31.4M-$18.9M-$9.2M60.9%
FY 20232023-12-31$24.0M-$22.1M-$13.7M61.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLPT)

  • ✓Walkthrough of CLPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.56%▼ DESCENDING CHANNEL
2026-11-03O $10.69H $10.69L $10.67C $10.67VOL 916.6K
RES: $14.89SUP: $8.80SMA50: $12.32SMA200: $12.92
$20.38$17.27$14.16$11.05$7.95RES $14.89SUP $8.80$10.672026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLPT Butterfly Map → + Track CLPT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +17.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLPT)

Health Care Rank #994 of 1016 ⚔️ MOBI vs CLPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLPT vs. MOBI, EMBC, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ClearPoint Neuro Inc. (CLPT) ranks #994 by composite RQD confidence (19/100, grade E) and #500 by equity capitalization ($342.0M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with CLPT at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLPT ACTIVE
ClearPoint Neuro Inc.
E 19/100 — 61.4% -35.0% -0.19% $342.0M Benchmark Subject
MOBI
Mobia Medical Inc.
D 50/100 — — — -6.12% $352.2M /mobi-vs-clpt →
EMBC
Embecta Corp.
C+ 68/100 3.9x 62.6% 35.5% -4.73% $354.1M /embc-vs-clpt →
OFIX
Orthofix Medical Inc.
D- 42/100 — 68.8% -12.2% -11.43% $369.4M /ofix-vs-clpt →
SI
Shoulder Innovations Inc.
D 44/100 — 76.5% -16.1% -6.41% $398.3M /si-vs-clpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285550

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported GAAP revenue of $37.0M (+17.8% vs. FY2024 revenue of $31.4M , and +54.3% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of -$23.9M, and free cash flow of -$24.4M (-164.7% YoY). On the balance sheet, CLPT closed FY2025 with $97.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $37.0M -$25.5M -$23.9M -$24.4M $97.7M —
FY2024 (FY) 2024-12-31 $31.4M -$18.9M -$8.9M -$9.2M $39.2M —
FY2023 (FY) 2023-12-31 $24.0M -$22.1M -$13.7M -$13.7M — —

3. CLPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $10.67 (-0.19% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

How does CLPT compare to MOBI and EMBC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLPT?

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLPT trading relative to its 50-day, 200-day, and 52-week technical levels?

CLPT last traded at $10.67 (-0.19% on volume of 916,551 shares), positioning the stock -13.39% below its 50-day simple moving average ($12.32) and -17.41% below its 200-day simple moving average ($12.92). Across its 52-week range of $8.27 to $19.68, CLPT sits at the 21.0% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($9.47 to $11.87).

CLPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CLPT's next earnings date?

Based on SEC filing cadence, ClearPoint Neuro Inc. (CLPT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CLPT stock expected to move on earnings?

Volatility modeling currently projects a ±11.2% event move for CLPT, spanning a range between $9.47 and $11.87.

Direct Sub-Reports: CLPT RQD Cockpit CLPT 12M Forecast CLPT Earnings & Move CLPT Dividends & DRIP CLPT Insiders & 13F CLPT Whale Options CLPT Profit Sankey CLPT News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLPT — ClearPoint Neuro Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CLPT scores 19 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 2 / 20 (ROIC -35%; FCF yield -7.13%), indicating the business is not currently generating returns on capital or positive free cash flow. The Whale 13F Flow pillar scores 5 / 20 for institutional accumulation and options positioning, the Insider Conviction pillar scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, and the Macro Regime Fit pillar scores 3 / 20 (Beta 1.0; sector sensitivity). The Forensic Balance Sheet pillar scores 6 / 20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5), which is the weakest structural signal in the financial-distress assessment. For a prospective investor, the upside case rests on the reported gross margin of 61.4% and the revenue growth shown across FY 2023 to FY 2025, but the rating places more weight on negative operating economics, low Altman Z-Score reading, and weak insider and institutional support. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data; the stock's positioning within its $8.27 - $24.75 52-week range and $342.7M market capitalization should be read against these forensic signals. This analysis is educational and not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$37.0M$-24.2M$-25.5MN/A$-24.4M$45.9MN/A
FY 2024$31.4M$-19.7M$-18.9MN/A$-9.2M$20.1MN/A
FY 2023$24.0M$-22.4M$-22.1MN/A$-13.7MN/AN/A

Per the SEC financials, operating and net losses persisted across all three reported periods, with operating margin at -60% and net margin at -60% per the market data section. Gross margin is reported at 61.4%. ROIC is -35% per the market data section and the Roarable RQD rating. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9 per the Forensic Balance Sheet pillar. Debt/Equity is 0.5 per the same pillar, while debt values in the SEC financials are N/A.

Recent Catalysts & News Wire Analysis

  • RISK WATCH (RED): A Yahoo Finance report headlined that CLPT reported a Q3 loss and missed revenue estimates.
  • MARKET WIRE (YELLOW): A www.debelegger.nl report carried a general stock price and chart headline.
  • CATALYST (GREEN): A GuruFocus report headlined revenue growth in Q3 and a reference to a gene-related item.
  • MARKET WIRE (YELLOW): A Benzinga report carried the Q3 2026 earnings call transcript headline.
  • RISK WATCH (RED): A Simply Wall St report headlined cash runway and loss pressure.
  • RISK WATCH (RED): A Pluang report headlined a lawsuit probing CLPT over a stock drop following a Huntington's drug trial setback.

The Butterfly Supply-Chain Graph reports sector Health Care, industry Medical/Dental Instruments, supply chain NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the FY 2025 debt balances, given that debt is reported as N/A across all periods?
  • What EPS, P/E, and EV/EBITDA figures apply, since these are not available in source data?
  • What is the outcome of the lawsuit referenced in the Pluang report, and what is its potential financial exposure?
  • What is the company's cash runway given the FY 2025 FCF of $-24.4M against $45.9M cash?
  • What drove the FY 2025 revenue increase and does it reflect durable demand?

CLPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ClearPoint Neuro Inc. (CLPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLPT Bull vs. Bear Conversation Board — What's Your Call at $10.67?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLPT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CLPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.41 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLPT (E • RQD 19/100) a Buy at $10.69?

Welcome to the CLPT (ClearPoint Neuro Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.77 (-18.0%)
Spot @ $10.69

Pump the brakes on CLPT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLPT, but look at what you are paying: current EV/EBITDA multiples with 61.4% gross margins. Unless ClearPoint Neuro Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.47 (+26.0%)
Spot @ $10.69

CLPT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLPT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $10.69 (52-wk range $8.27 - $24.75), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%